ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) have received an average rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $14.20.

Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, April 14th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. HC Wainwright lifted their price objective on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Finally, BTIG Research set a $12.00 price objective on ImmunityBio in a report on Friday.

Insider Activity

In other ImmunityBio news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the transaction, the director directly owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. The trade was a 2.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 275,000 shares of company stock valued at $2,934,500. 69.48% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. grew its holdings in ImmunityBio by 11.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 39,030 shares of the company’s stock valued at $299,000 after buying an additional 3,930 shares in the last quarter. Cutler Investment Counsel LLC purchased a new position in shares of ImmunityBio during the first quarter worth about $767,000. Dimensional Fund Advisors LP grew its holdings in shares of ImmunityBio by 345.3% during the first quarter. Dimensional Fund Advisors LP now owns 110,009 shares of the company’s stock worth $844,000 after purchasing an additional 85,305 shares in the last quarter. KBC Group NV purchased a new position in shares of ImmunityBio during the first quarter worth about $79,000. Finally, SEB Asset Management AB purchased a new position in shares of ImmunityBio during the first quarter worth about $18,770,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio reported record Q1 2026 results, with net product revenue rising nearly 2.7x year over year to about $44.2 million, and management highlighted continued commercial growth for ANKTIVA. Article: ImmunityBio Reports Record Q1 2026 Results
• Neutral Sentiment: The company’s quarterly loss was larger than expected, but revenue came in above estimates, leaving investors focused more on the growth outlook than the earnings miss. Article: ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
• Neutral Sentiment: A separate market note said traders are watching a key FDA decision on Anktiva, which could be an important catalyst for the stock but adds regulatory uncertainty. Article: IBRX stock enters heavy catalyst phase
• Negative Sentiment: Multiple law firms are advertising class-action lawsuits and lead-plaintiff deadlines, following allegations that ImmunityBio made misleading statements about Anktiva and drug-promotion claims after an FDA warning letter. Article: IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws

ImmunityBio Price Performance

NASDAQ IBRX opened at $8.51 on Monday. The business’s fifty day moving average is $8.00 and its 200-day moving average is $5.18. ImmunityBio has a one year low of $1.95 and a one year high of $12.43. The stock has a market capitalization of $8.91 billion, a price-to-earnings ratio of -10.01 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The company had revenue of $44.21 million during the quarter, compared to the consensus estimate of $43.07 million. Research analysts expect that ImmunityBio will post -0.31 EPS for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.